These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29976734)

  • 1. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
    Takahashi N; Nishiwaki K; Nakaseko C; Aotsuka N; Sano K; Ohwada C; Kuroki J; Kimura H; Tokuhira M; Mitani K; Fujikawa K; Iwase O; Ohishi K; Kimura F; Fukuda T; Tanosaki S; Takahashi S; Kameoka Y; Nishikawa H; Wakita H;
    Haematologica; 2018 Nov; 103(11):1835-1842. PubMed ID: 29976734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
    Nagafuji K; Matsumura I; Shimose T; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Kadowaki N; Ishikawa J; Imamura Y; Yamazaki H; Akashi K; Kanakura Y
    Int J Hematol; 2019 Dec; 110(6):675-682. PubMed ID: 31538327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
    Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
    Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
    Noguchi S; Nakaseko C; Nishiwaki K; Ogasawara H; Ohishi K; Tokuhira M; Noguchi M; Kimura H; Handa H; Mitani K; Miura M; Wakita H; Takahashi N;
    Int J Hematol; 2018 Aug; 108(2):176-183. PubMed ID: 29713954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
    Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
    J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
    Hochhaus A; Masszi T; Giles FJ; Radich JP; Ross DM; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; García-Gutiérrez V; Gattermann N; Wiktor-Jedrzejczak W; le Coutre PD; Martino B; Saussele S; Menssen HD; Deng W; Krunic N; Bedoucha V; Saglio G
    Leukemia; 2017 Jul; 31(7):1525-1531. PubMed ID: 28218239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
    Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
    Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
    Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
    Gugliotta G; Castagnetti F; Breccia M; Levato L; D'Adda M; Stagno F; Tiribelli M; Salvucci M; Fava C; Martino B; Cedrone M; Bocchia M; Trabacchi E; Cavazzini F; Usala E; Russo Rossi A; Bochicchio MT; Soverini S; Alimena G; Cavo M; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G;
    Haematologica; 2015 Sep; 100(9):1146-50. PubMed ID: 26113419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
    Kimura S; Imagawa J; Murai K; Hino M; Kitawaki T; Okada M; Tanaka H; Shindo M; Kumagai T; Ikezoe T; Uoshima N; Sato T; Watanabe R; Kowata S; Hayakawa M; Hosoki T; Ikeda K; Kobayashi T; Kakinoki Y; Nishimoto T; Takezako N; Shibayama H; Takaori-Kondo A; Nakamae H; Kawaguchi A; Ureshino H; Sakamoto J; Ishida Y;
    Lancet Haematol; 2020 Mar; 7(3):e218-e225. PubMed ID: 31978329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
    Imagawa J; Tanaka H; Okada M; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Morita S; Sakamoto J; Kimura S;
    Lancet Haematol; 2015 Dec; 2(12):e528-35. PubMed ID: 26686407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
    Hughes TP; Clementino NCD; Fominykh M; Lipton JH; Turkina AG; Moiraghi EB; Nicolini FE; Takahashi N; Sacha T; Kim DW; Fellague-Chebra R; Tiwari R; Bouard C; Mahon FX
    Leukemia; 2021 Jun; 35(6):1631-1642. PubMed ID: 33980976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
    Hochhaus A; Rosti G; Cross NC; Steegmann JL; le Coutre P; Ossenkoppele G; Petrov L; Masszi T; Hellmann A; Griskevicius L; Wiktor-Jedrzejczak W; Rea D; Coriu D; Brümmendorf TH; Porkka K; Saglio G; Gastl G; Müller MC; Schuld P; Di Matteo P; Pellegrino A; Dezzani L; Mahon FX; Baccarani M; Giles FJ
    Leukemia; 2016 Jan; 30(1):57-64. PubMed ID: 26437782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
    Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.